Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

BioNanoTech aims to usher in new frontier in protein purification

By Brian Buntz | September 22, 2022

BionanotechStartup BioNanoTech has developed a patented platform technology for purifying proteins/antibodies across size ranges.

In particular, the company has developed a new class of Immobilization Metal Affinity Chromatography (IMAC) nanoresins.

“We are building something new at a new scale, and something that can do chemistry and physics on a scale that is more closely to what the target molecules are,” said John Harrold, chief scientific officer at BioNanoTech.

Onyema Osuagwu

Onyema Osuagwu

While IMAC has existed for more than four decades, the technology traditionally has not been able to capture a wide range of proteins. “This is problematic because these are the starting points for what will be coming later on biologic drugs,” BioNanoTech CEO Onyema Osuagwu said.

Traditional drawbacks of IMAC include metal-ion leaching, size-variant protein capacity and denaturation of some proteins.

BioNanoTech has developed a new class of patented IMAC nanoresins to overcome those hurdles. The company says its resins offer reduced or no metal leaching and size-invariant protein capacity.

John Harrold

John Harrold

“We’ve nano-engineered a new type of support for our platform that gives us that ability to deploy IMAC resins and other technologies that we’re also developing,” Osuagwu said.

In addition to IMAC resins, the company has also developed immunoaffinity chromatography (IAC) nanoresins that offer similar advantages in the purification of monoclonal antibodies. The IAC resins also support high capacity and purity.

The company says its new resins also offer high purity in a single-step separation of cytosolic and membrane proteins with less denaturing than current technologies.

BioNanoTech is targeting customers across the biotech sector, including R&D scientists in the pharmaceutical industry and academia.

“The first and most important thing is workflow reduction,” Osuagwu said. “Because we have so much higher purity and much more specificity in how we set it up, we can reduce steps.”

“The step reduction is powerful — especially in the R&D phase,” Osuagwu added. “We’ve gotten a lot of good commentary on that.”

Another factor differentiating BioNanoTech in drug discovery is its focus on physics. “We’re working with something that is more on the scale of biomolecules. And our materials are on the same scale, which means that the physics gets a lot more involved than, say, something like the ensemble effects of chemistry,” Harrold said.

BioNanoTech has secured funding twice from the National Science Foundation (NSF). In addition, the company is a recipient of I-Corps NSF funding. It has also received financial backing from the Small Business Innovation Research (SBIR) program.

“We actually were very intentional about where we took dollars,” Osuagwu said. “In addition to being able to help the widest number of people, we wanted to exert some level of control so we can understand the intentions of those we partner with.”


Filed Under: Drug Discovery and Development
Tagged With: BioNanoTech
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Collage of close-up male and female eyes isolated on colored neon backgorund. Multicolored stripes. Concept of equality, unification of all nations, ages and interests. Diversity and human rights
How a ‘rising tide’ of inclusivity is transforming clinical trials
Mary Marcus appointed CEO of NewAge Industries
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
Data analytics tools help doctors analyze trends in patient outcomes and population health.
External comparator studies: What researchers need to know to minimize bias
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE